David P. Wood, Jr., MD gave a presentation at the 9th International Prostate Forum (IPF) on October 8 - 10, 2009 in Izmir, Turkey on the Management the side effects of hormone therapy (ADT) when used to treat of prostate cancer. Dr. Wood indicated that the three major side effects of ADT in the treatment [...]
One of the most heated debates in prostate cancer care is around the use of 5-reductase inhibitors (5ARI) like Dutasteride as a third component of a hormone blockade (ADT3). 5-ARIs block the conversion of testosterone to dihydrotestosterone (DHT). DHT is thought to be an extremely powerful “fuel” for the growth of prostate cancer. However, there [...]
The relatively new drug, denosumab, has proven itself very effective for men on a hormone blockade (ADT). In a recently completed 3-year, randomized, double-blind study at the Massachusetts General Hospital Cancer Center, Boston, Massachusetts, denosumab significantly increased bone mineral density and decreased new vertebral fractures in men receiving ADT for the treatment of advanced prostate [...]
Advanced prostate cancer will progress and most of us will face a time when Androgen Deprivation Therapy (ADT) stops working. Most men on ADT take a LHRH agonist, which turns off the production of testosterone (i.e. Lupron) along with a non-steroidal anti-androgen (i.e. Casodex) that prevents the small amount of testosterone that continues to be [...]
It is inevitable; most men with prostate cancer, who require treatment with androgen deprivation therapy (ADT), will eventually become resistance to treatment leading to the development of metastatic disease. Men who develop metastatic castrate-resistant disease have a very poor prognosis. Historically, their overall survival is estimated only to be 24 to 36 months. A study [...]